Pictet Asset Management SA raised its position in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) by 13.0% in the 2nd quarter, Holdings Channel reports. The fund owned 481,827 shares of the specialty pharmaceutical company’s stock after acquiring an additional 55,556 shares during the period. Pictet Asset Management SA’s holdings in Paratek Pharmaceuticals were worth $930,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. National Asset Management Inc. lifted its stake in shares of Paratek Pharmaceuticals by 33.1% in the first quarter. National Asset Management Inc. now owns 46,200 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 11,500 shares during the period. CM Management LLC lifted its stake in shares of Paratek Pharmaceuticals by 16.7% in the first quarter. CM Management LLC now owns 350,000 shares of the specialty pharmaceutical company’s stock valued at $1,040,000 after purchasing an additional 50,000 shares during the period. GSA Capital Partners LLP lifted its stake in shares of Paratek Pharmaceuticals by 52.0% in the first quarter. GSA Capital Partners LLP now owns 79,448 shares of the specialty pharmaceutical company’s stock valued at $236,000 after purchasing an additional 27,192 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Paratek Pharmaceuticals by 28.9% in the first quarter. JPMorgan Chase & Co. now owns 28,946 shares of the specialty pharmaceutical company’s stock valued at $86,000 after purchasing an additional 6,497 shares during the period. Finally, 1492 Capital Management LLC lifted its stake in shares of Paratek Pharmaceuticals by 3.8% in the first quarter. 1492 Capital Management LLC now owns 509,828 shares of the specialty pharmaceutical company’s stock valued at $1,514,000 after purchasing an additional 18,795 shares during the period. Institutional investors and hedge funds own 54.58% of the company’s stock.
Paratek Pharmaceuticals Trading Up 10.4 %
Shares of PRTK opened at $2.13 on Wednesday. The stock has a market cap of $118.32 million, a P/E ratio of -1.25 and a beta of 1.51. The company has a 50-day moving average of $2.74 and a two-hundred day moving average of $2.44. Paratek Pharmaceuticals, Inc. has a 12-month low of $1.60 and a 12-month high of $4.95.
Wall Street Analyst Weigh In
Insiders Place Their Bets
In other Paratek Pharmaceuticals news, CEO Evan Loh sold 8,805 shares of Paratek Pharmaceuticals stock in a transaction dated Friday, October 28th. The shares were sold at an average price of $3.47, for a total transaction of $30,553.35. Following the completion of the transaction, the chief executive officer now owns 1,278,937 shares in the company, valued at $4,437,911.39. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders sold 23,750 shares of company stock worth $82,413. Insiders own 8.00% of the company’s stock.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.
- Get a free copy of the StockNews.com research report on Paratek Pharmaceuticals (PRTK)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.